{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:06:56Z","timestamp":1789056416864,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["AR079572"],"award-info":[{"award-number":["AR079572"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omta.2026.201800","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:49:02Z","timestamp":1782863342000},"page":"201800","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Highly potent MyoAAV4A vector reverses GSD III pathology in aged mice and enables long-term muscle disease correction in young adult mice"],"prefix":"10.1016","volume":"34","author":[{"given":"Kuo-An","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqing","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8869-4531","authenticated-orcid":false,"given":"Haoyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Eisner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah P.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2191-0025","authenticated-orcid":false,"given":"Baodong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201800_bib1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bbacli.2016.02.001","article-title":"Glycogen metabolism in humans","volume":"5","author":"Adeva-Andany","year":"2016","journal-title":"BBA Clin."},{"key":"10.1016\/j.omta.2026.201800_bib2","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/GIM.0b013e3181e655b6","article-title":"Glycogen storage disease type III diagnosis and management guidelines","volume":"12","author":"Kishnani","year":"2010","journal-title":"Genet. Med."},{"key":"10.1016\/j.omta.2026.201800_bib3","first-page":"72","article-title":"Clinical, biochemical and genetic features of glycogen debranching enzyme deficiency","volume":"26","author":"Lucchiari","year":"2007","journal-title":"Acta Myol."},{"key":"10.1016\/j.omta.2026.201800_bib4","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2006.09.022","article-title":"Glycogen storage disease type III-hepatocellular carcinoma a long-term complication?","volume":"46","author":"Demo","year":"2007","journal-title":"J. Hepatol"},{"key":"10.1016\/j.omta.2026.201800_bib5","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1038\/s41436-019-0561-7","article-title":"Liver fibrosis during clinical ascertainment of glycogen storage disease type III: a need for improved and systematic monitoring","volume":"21","author":"Halaby","year":"2019","journal-title":"Genet. Med."},{"key":"10.1016\/j.omta.2026.201800_bib6","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s10545-016-9932-2","article-title":"Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome","volume":"39","author":"Sentner","year":"2016","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.omta.2026.201800_bib7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/jimd.12355","article-title":"Narrative review of glycogen storage disorder type III with a focus on neuromuscular, cardiac and therapeutic aspects","volume":"44","author":"Berling","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.omta.2026.201800_bib8","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/GIM.0b013e3181e0e979","article-title":"Echocardiographic manifestations of Glycogen Storage Disease III: Increase in wall thickness and left ventricular mass over time","volume":"12","author":"Vertilus","year":"2010","journal-title":"Genet. Med."},{"key":"10.1016\/j.omta.2026.201800_bib9","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10545-014-9756-x","article-title":"Dietary management in glycogen storage disease type III: what is the evidence?","volume":"38","author":"Derks","year":"2015","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.omta.2026.201800_bib10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10545-009-1088-x","article-title":"Reversal of glycogen storage disease type IIIa-related cardiomyopathy with modification of diet","volume":"32 Suppl 1","author":"Dagli","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.omta.2026.201800_bib11","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13023-014-0196-3","article-title":"Glycogen storage disease type III: modified Atkins diet improves myopathy","volume":"9","author":"Mayorandan","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omta.2026.201800_bib12","article-title":"Improvement in hypertrophic cardiomyopathy after using a high-fat, high-protein and low-carbohydrate diet in a non-adherent child with glycogen storage disease type IIIa","volume":"32","author":"Kumru Akin","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.omta.2026.201800_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2023.1178348","article-title":"Nutritional management of glycogen storage disease type III: a case report and a critical appraisal of the literature","volume":"10","author":"Massimino","year":"2023","journal-title":"Front. Nutr."},{"key":"10.1016\/j.omta.2026.201800_bib14","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.omtm.2020.05.034","article-title":"A Novel Gene Therapy Approach for GSD III Using an AAV Vector Encoding a Bacterial Glycogen Debranching Enzyme","volume":"18","author":"Lim","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201800_bib15","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.152970","article-title":"Suppression of pullulanase-induced cytotoxic T cell response with a dual promoter in GSD IIIa mice","volume":"7","author":"Lim","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.omta.2026.201800_bib16","article-title":"Long-Term Correction of Murine Glycogen Storage Disease Type III by AAV-Mediated Gene Therapy Using an Immunotolerizing Dual Promoter to Express Bacterial Pullulanase","volume":"17","author":"Liao","year":"2025","journal-title":"Adv. Cell Gene Ther."},{"key":"10.1016\/j.omta.2026.201800_bib17","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1016\/j.cell.2021.08.028","article-title":"Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species","volume":"184","author":"Tabebordbar","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.omta.2026.201800_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101567","article-title":"High-potency MyoAAV capsids enhanced skeletal muscle correction in a mouse model of GSD IIIa","volume":"33","author":"Liao","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201800_bib19","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1373\/clinchem.2011.178319","article-title":"Rapid ultraperformance liquid chromatography-tandem mass spectrometry assay for a characteristic glycogen-derived tetrasaccharide in Pompe disease and other glycogen storage diseases","volume":"58","author":"Sluiter","year":"2012","journal-title":"Clin. Chem."},{"key":"10.1016\/j.omta.2026.201800_bib20","article-title":"Urine glucose tetrasaccharide: A good biomarker for glycogenoses type II and III? A study of the French cohort","volume":"23","author":"Piraud","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.omta.2026.201800_bib21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omta.2026.201800_bib22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ymthe.2006.03.014","article-title":"Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8","volume":"14","author":"Inagaki","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201800_bib23","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/mt.2008.76","article-title":"Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection","volume":"16","author":"Zincarelli","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201800_bib24","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","article-title":"Lethal immunotoxicity in high-dose systemic AAV therapy","volume":"31","author":"Duan","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201800_bib25","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1089\/hum.2020.182","article-title":"Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy","volume":"31","author":"Wilson","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201800_bib26","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.ymthe.2020.07.009","article-title":"Broader Implications of Progressive Liver Dysfunction and Lethal Sepsis in Two Boys following Systemic High-Dose AAV","volume":"28","author":"Morales","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201800_bib27","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.1038\/s41467-024-50569-6","article-title":"Systemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice","volume":"15","author":"Zhou","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201800_bib28","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/s41467-025-57831-5","article-title":"Activation of endogenous full-length utrophin by MyoAAV-UA as a therapeutic approach for Duchenne muscular dystrophy","volume":"16","author":"Wu","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201800_bib29","article-title":"MyoAAV-delivered sup-tRNA increases full-length dystrophin expression","volume":"12","author":"Ai","year":"2025","journal-title":"Genes Dis."},{"key":"10.1016\/j.omta.2026.201800_bib30","first-page":"41","article-title":"Natural Progression of Canine Glycogen Storage Disease Type IIIa","volume":"66","author":"Brooks","year":"2016","journal-title":"Comp. Med."},{"key":"10.1016\/j.omta.2026.201800_bib31","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1089\/hum.2010.055","article-title":"Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale","volume":"21","author":"Lock","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201800_bib32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0003-2697(03)00056-3","article-title":"Analysis of a glucose tetrasaccharide elevated in Pompe disease by stable isotope dilution\u2013electrospray ionization tandem mass spectrometry","volume":"316","author":"Young","year":"2003","journal-title":"Anal. Biochem."}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26001357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26001357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:14:12Z","timestamp":1789053252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X26001357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S3117387X26001357"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201800","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Highly potent MyoAAV4A vector reverses GSD III pathology in aged mice and enables long-term muscle disease correction in young adult mice","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201800","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201800"}}